Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing

Retina. May-Jun 2006;26(5):519-22. doi: 10.1097/01.iae.0000225354.92444.7a.

Abstract

Purpose: To determine the change in anti-vascular endothelial growth factor (VEGF) activity of bevacizumab (Avastin, Genentech, Inc., San Francisco, CA) after refrigeration or freezing.

Methods: Samples of bevacizumab were drawn up from new vials into plastic tuberculin syringes and refrigerated at 4 degrees C for 1 week, 3 weeks, 1 month, 3 months, and 6 months. The vials and syringes were stored at 4 degrees C, and the syringes were capped with a needle. One syringe was frozen at -10 degrees C. The bevacizumab concentration was measured, via its binding to VEGF-165.

Results: The percentage of degradation of bevacizumab in the previously pierced vials stored at 4 degrees C compared with that in the unpierced vial was 9.6% at 3 months and 12.7% at 6 months. The bevacizumab drawn into the syringe and stored at 4 degrees C was degraded by 1.6% at 1 week, 0% at 3 weeks, 8.8% at 3 months, and 15.9% at 6 months. The bevacizumab frozen in a syringe at -10 degrees C was degraded by 12.0% at 6 months.

Conclusion: The anti-VEGF activity of bevacizumab may degrade minimally over time, with storage.

MeSH terms

  • Angiogenesis Inhibitors / chemistry*
  • Angiogenesis Inhibitors / metabolism
  • Antibodies, Monoclonal / chemistry*
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Biological Availability
  • Cold Temperature*
  • Drug Stability
  • Drug Storage
  • Freezing*
  • Immunoassay
  • Ophthalmic Solutions / chemistry
  • Ophthalmic Solutions / metabolism
  • Plastics
  • Protein Binding
  • Recombinant Proteins / metabolism
  • Syringes*
  • Time Factors
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Ophthalmic Solutions
  • Plastics
  • Recombinant Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab